[Demonstration and characterization of EGF receptors in cancer of the uterine cervix].
Epidermal Growth Factor in a polypeptide growth factor of which receptor EGFR has a prognosis value for some malignant tumours. Data are limited concerning the EGFR value in cervix tumours. EGFR was measured in biopsies obtained in cervix cancer patients before any treatment. Twenty-two patients (18 squamous carcinomas, 4 adenocarcinomas) were studied. EGF binding was characterized in seven tumour samples. Scatchard representation identified a single family of binding sites. Kd value revealed high affinity for EGF binding: 0.645 +/- 0.769 nmol/l. EGFR values were determined by a simplified competition method using a radiolabeled ligand. EGFR was found to be more elevated in tumours (n = 20) than in normal tissue (n = 4): (59.5 vs 10.5 fmol/mg proteins). There was a tendency for higher EGFR values in squamous tumours (m = 83.5 fmol/mg proteins) as compared to adenocarcinomas (m = 35.5 fmol/mg proteins), P = 0.09. There was no difference in the distribution of EGFR values according to tumour differentiation and staging. This work confirms the presence of EGFR in cervix tumours. Interestingly, we found that tumours with high EGFR values were more radiosensitive than tumours with low values.
Lagrange
J L
JL
Service de radiothérapie-curiethérapie, centre Antoine-Lacassagne, Nice, France.
Francoual
M
M
Formento
J L
JL
Del Guidice
P
P
Bensadoun
R J
RJ
Teissier
E
E
Ettore
F
F
Gillet
J Y
JY
Namer
M
M
Milano
G
G
D000230:Adenocarcinoma / Q000737:chemistry / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000628:therapy; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000628:therapy
D066246:ErbB Receptors
Mise en évidence et caractérisation des récepteurs d'EGF dans les cancers du col de l'utérus.